Replacement therapy in Addison’s disease

Bibliography

• OELKERS W: Adrenal insufficiency. N Engl. J. Med. (1996) 335:1206–1212.
   PubMed Web of Science ®Google Scholar
• ARLT W, ALLOLIO B: Adrenal insufficiency. Lancet (2003) 361:1881–1893.
   PubMed Web of Science ®Google Scholar
• LABRIE F, LUU-THE V, LABRIE C et al: Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. Endocr. Rev (2003) 24:152–182.
   PubMed Web of Science ®Google Scholar
• LOVAS K, HUSEBYE ES: High prevalence and increasing incidence of Addison's disease in western Norway. Clin. Endocrine]. (Ox!) (2002) 56:787–791.
   PubMed Web of Science ®Google Scholar
• WINQVIST 0, KARLSSON FA, KAMPE 0: 21-Hydroxylase, a major autoantigen in idiopathic Addison's disease. Lancet (1992) 339:1559–1562.
   PubMed Web of Science ®Google Scholar
• TENS, NEW M, MACLAREN N: Clinical review 130: Addison's disease 2001. Clin. Endocrine]. Metab. (2001) 86:2909–2922.
   PubMedGoogle Scholar
• RIEDEL M, WIESE A, SCHURMEYER TH, BRABANT G: Quality of life in patients with Addison's disease: effects of different cortisol replacement modes. Exp. Clin. Endocrine]. (1993) 101:106–111.
   PubMedGoogle Scholar
• ARLT W, CALLIES F, VAN VLIJMEN JC et al.: Dehydroepiandrosterone replacement in women with adrenal insufficiency. N Engl. J. Med. (1999) 341:1013–1020.
   Google Scholar
• HUNT PJ, GURNELL EM, HUPPERT FA et al.: Improvement inmood and fatigue afterdehydroepiandrosterone replacement in Addison's disease in a randomized, double blind trial. j Clin. Endocrine]. Metab. (2000) 85:4650–4656.
   PubMed Web of Science ®Google Scholar
• JOHANNSSON G, BURMAN P,WIREN L et al.: Low dosedehydroepiandrosterone affects behavior in hypopituitary androgen-deficient women: a placebo-controlled trial. I Clin. Endocrine]. Metab. (2002) 87:2046–2052.
   Google Scholar
• LOVAS K, LOGE JH, HUSEBYE ES: Subjective health status in Norwegian patients with Addison's disease.Clin. Endocrine]. (Ox!) (2002) 56:581–588.
   PubMed Web of Science ®Google Scholar
• LOVAS K, GEBRE-MEDHIN G, TROVIK TS et al.: Replacement of dehydroepiandrosterone in adrenal failure: no benefit for subjective health status and sexuality in a 9-month, randomized, parallel group clinical trial. I Clin. Endocrine]. Metab. (2003) 88:1112–1118.
   PubMed Web of Science ®Google Scholar
• WICHERS M, SPRINGER W,BIDLINGMAIER F, KLINGMULLER D: The influence of hydrocortisone substitution on the quality of life and parameters of bone metabolism in patients with secondary hypocortisolism.Clin. Endocrine]. (Ox!) (1999) 50:759–765.
   PubMed Web of Science ®Google Scholar
• AL-SHOUMER KA, BESHYAH SA, NITHTHYANANTHAN R, JOHNSTON DG: Effect of glucocorticoid replacement therapy on glucose tolerance and intermediary metabolites in hypopituitary adults. Clin. Endocrine]. (Ox!) (1995) 42:85–90.
   PubMedGoogle Scholar
• DEVOGELAER JP, CRABBE J, NAGANTDE DEUXCHAISNES C: Bone mineral density in Addison's disease: evidence for an effect of adrenal androgens on bone mass. Br. Med. J. (1987) 294:798–800.
   PubMed Web of Science ®Google Scholar
• ZELISSEN PM, CROUGHS RJ, VAN RIJK PP, RAYMAKERS JA: Effect of glucocorticoid replacement therapy on bone mineral density in patients with Addison disease. Ann. Intern. Med. (1994) 120:207–210.
   PubMed Web of Science ®Google Scholar
• FLORKOWSKI CM, HOLMES SJ, ELLIOT JR, DONALD RA,ESPINER EA: Bone mineral density is reduced in female but not male subjects with Addison's disease. NZ Med. 1 (1994) 107:52-53.
   Google Scholar
• VALERO MA, LEON M, RUIZ VALDEPENAS MP et al: Bone density and turnover in Addison's disease: effect of glucocorticoid treatment. Bone Miner. (1994) 26:9–17.
   PubMedGoogle Scholar
• BRAATVEDT GD, JOYCE M, EVANS M, CLEARWATER J, REID IR: Bone mineral density in patients with treated Addison's disease. Osteoporos. hat. (1999) 10:435–440.
   PubMed Web of Science ®Google Scholar
• JODAR E, VALDEPENAS MP, MARTINEZ G, JARA A, HAWKINS F: Long-term follow-up of bone mineral density in Addison's disease.Clin. Endocrine]. (Ox!) (2003) 58:617–620.
   PubMed Web of Science ®Google Scholar
• ESTEBAN NV, LOUGHLIN T, YERGEY AL et al.: Daily cortisol production rate in man determined by stable isotope dilution/mass spectrometry.Clin. Endocrinol Metab. (1991) 72:39–45.
   Google Scholar
• KERRIGAN JR, VELDHUIS JD,LEYO SA, IRANMANESH A,ROGOL AD: Estimation of daily cortisol production and clearance rates in normal pubertal males by deconvolution analysis.Clin. Endocrinol Metab. (1993) 76:1505–1510.
   Google Scholar
• KRAAN GP, DULLAART RP, PRATT JJ et al.: The daily cortisol production reinvestigated in healthy men. The serum and urinary cortisol production rates are not significantly different. I Clin. Endocrinol Metab. (1998) 83:1247–1252.
   Google Scholar
• JEFFCOATE W: Assessment of corticosteroid replacement therapy in adults with adrenal insufficiency. Ann. Chit. Biochem. (1999) 36:151–157.
   PubMed Web of Science ®Google Scholar
• SCOTT RS, DONALD RA,ESPINER EA: Plasma ACTH and cortisol profiles in Addisonian patients receiving conventional substitution therapy.Clin. Endocrinol OD (1978) 9:571–576.
   PubMed Web of Science ®Google Scholar
• FEEK CM, RATCLIFFE JG, SETH J et al: Patterns of plasma cortisol and ACTH concentrations in patients with Addison's disease treated with conventional corticosteroid replacement. Chit. Endocrinol (Ox!) (1981) 14:451–458.
   PubMed Web of Science ®Google Scholar
• HOWLETT TA: An assessment of optimal hydrocortisone replacement therapy [see comments]. Chit. Endocrinol OD (1997) 46:263–268.
   PubMed Web of Science ®Google Scholar
• PEACEY SR, GUO CY, ROBINSON AM et al.: Glucocorticoid replacement therapy: are patients over treated and does it matter? Chit. Endocrinol OD (1997) 46:255–261.
   PubMed Web of Science ®Google Scholar
• ORTH DN, KOVACS WJ: The adrenal cortex. In: Williams textbook ofendocrinology Williams RH, Foster DW, Kronenberg HM et al. (Eds), WB Saunders, Philadelphia, PA, USA (1998):517–664.
   Google Scholar
• DIEDERICH S, EIGENDORFF E, BURKHARDT P et al.:11beta-hydroxysteroid dehydrogenase types 1 and 2: an important pharmacokinetic determinant for the activity of synthetic mineralo- and glucocorticoids. Clin. Endocrinol Metab. (2002) 87:5695–5701.
   Google Scholar
• ALLOLIO B, ARLT W: DHEA treatment: myth or reality? Trends Endocrinol Metab. (2002) 13:288.
   Google Scholar
• MELLON SH, GRIFFIN LD: Neurosteroids: biochemistry and clinical significance. Trends Endocrinol Metab. (2002) 13:35–43.
   PubMed Web of Science ®Google Scholar
• MORALES AJ, NOLAN JJ, NELSON JC, YEN SS: Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. J. Chit. Endocrinol Metab. (1994) 78:1360–1367.
   PubMed Web of Science ®Google Scholar
• BAULIEU EE, THOMAS G, LEGRAIN S et al.: Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: contribution of the DHEAge Study to a sociobiomedical issue. Proc. Natl. Acad. Sci. USA (2000) 97:4279–4284.
   PubMed Web of Science ®Google Scholar
• BARNHART KT, FREEMAN E, GRISSO JA et al.: The effect of dehydroepiandrosterone supplementation to symptomatic perimenopausal women on serum endocrine profiles, lipid parameters, and health-related quality of life. Chit. Endocrinol Metab. (1999) 84:3896–3902.
   PubMed Web of Science ®Google Scholar
• ARLT W, CALLIES F, KOEHLER I et al:Dehydroepiandrosterone supplementation in healthy men with an age-related decline of dehydroepiandrosterone secretion. J. Chit. Endocrinol Metab. (2001) 86:4686–4692.
   PubMed Web of Science ®Google Scholar
• VAN NIEKERK JK, HUPPERT FA, HERBERT J: Salivary cortisol and DHEA: association with measures of cognition and well-being in normal older men, and effects of three months of DHEA supplementation. Psychoneumendocrinology (2001) 26:591–612.
   PubMed Web of Science ®Google Scholar
• FLYNN MA,WEAVER-OSTERHOLTZ D, SHARPE-TIMMS KL et al: Dehydroepiandrosterone replacement in aging humans. j. Chit. Endocrinol Metab. (1999) 84:1527–1533.
   PubMed Web of Science ®Google Scholar
• HUPPERT FA, VAN NIEKERK JK: Dehydroepiandrosterone (DHEA) supplementation for cognitive function. Cochrane Database Syst. Rev (2001) 2:CD000304.
   Google Scholar
• SHIFREN JL, BRAUNSTEIN GD, SIMON JA et al.: Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N Engl. J. Med. (2000) 343:682–688.
   PubMed Web of Science ®Google Scholar
• WU FCW, ECKARDSTEIN A: Androgens and coronary artery disease. Endocr: Rev. (2003) 24:183–217.
   PubMedGoogle Scholar
• WOODS JR, WILLIAMS JG, TAVEL M: The two-period crossover design in medical research. Ann. Intern. Med. (1989) 110:560–566.
   PubMed Web of Science ®Google Scholar